Phosphorylated tau and the neurodegenerative foldopathies

被引:104
作者
Kosik, KS
Shimura, H
机构
[1] Brigham & Womens Hosp, Harvard Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2005年 / 1739卷 / 2-3期
关键词
Hsc70; Hsp27; CHIP; Cdk5 and GSK3-beta; phosphorylated tau;
D O I
10.1016/j.bbadis.2004.10.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Many studies have implicated phosphorylated tau in the Alzheimer disease process. However, the cellular fate of phosphorylated tau has only recently been described. Recent work has shown that tau phosphorylation at substrate sites for the kinases Cdk5 and GSK3-beta can trigger the binding of tau to the chaperones Hsc70 and Hsp27. The binding of phosphorylated tau to Hsc70 implied that the complex may be a substrate for the E3 ligase CHIP and this possibility was experimentally verified. The presence of this system in cells suggests that phosphorylated tau may hold toxic dangers for cell viability, and the response of the cell is to harness a variety of protective mechanisms. These include binding to chaperones, which may prevent more toxic conformations of the protein, ubiquitination which will direct the protein to the proteasome, segregation of tau aggregates from the cellular machinery, and recruitment of Hsp27 which will confer anti-apoptotic properties to the cell. (C) 2004 Published by Elsevier B.V.
引用
收藏
页码:298 / 310
页数:13
相关论文
共 138 条
[91]  
Rao N, 2002, J LEUKOCYTE BIOL, V71, P753
[92]   Cerebral amyloid angiopathies: A pathologic, biochemical, and genetic view [J].
Revesz, T ;
Ghiso, J ;
Lashley, T ;
Plant, G ;
Rostagno, A ;
Frangione, B ;
Holton, JL .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2003, 62 (09) :885-898
[93]   Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination [J].
Rideout, HJ ;
Stefanis, L .
MOLECULAR AND CELLULAR NEUROSCIENCE, 2002, 21 (02) :223-238
[94]   Proteasomal inhibition leads to formation of ubiquitin/α-synuclein-immunoreactive inclusions in PC12 cells [J].
Rideout, HJ ;
Larsen, KE ;
Sulzer, D ;
Stefanis, L .
JOURNAL OF NEUROCHEMISTRY, 2001, 78 (04) :899-908
[95]   Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q2l-22 [J].
Rosso, SM ;
Kamphorst, W ;
de Graaf, B ;
Willemsen, R ;
Ravid, R ;
Niermeijer, MF ;
Spillantini, MG ;
Heutink, P ;
van Swieten, JC .
BRAIN, 2001, 124 :1948-1957
[96]   Hsp90 as a capacitor for morphological evolution [J].
Rutherford, SL ;
Lindquist, S .
NATURE, 1998, 396 (6709) :336-342
[97]   Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90 [J].
Schneider, C ;
SeppLorenzino, L ;
Nimmesgern, E ;
Ouerfelli, O ;
Danishefsky, S ;
Rosen, N ;
Hartl, FU .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14536-14541
[98]   Rapid degradation of a large fraction of newly synthesized proteins by proteasomes [J].
Schubert, U ;
Antón, LC ;
Gibbs, J ;
Norbury, CC ;
Yewdell, JW ;
Bennink, JR .
NATURE, 2000, 404 (6779) :770-774
[99]   Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases [J].
Sherman, MY ;
Goldberg, AL .
NEURON, 2001, 29 (01) :15-32
[100]   Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription [J].
Shimohata, T ;
Nakajima, T ;
Yamada, M ;
Uchida, C ;
Onodera, O ;
Naruse, S ;
Kimura, T ;
Koide, R ;
Nozaki, K ;
Sano, Y ;
Ishiguro, H ;
Sakoe, K ;
Ooshima, T ;
Sato, A ;
Ikeuchi, T ;
Oyake, M ;
Sato, T ;
Aoyagi, Y ;
Hozumi, I ;
Nagatsu, T ;
Takiyama, Y ;
Nishizawa, M ;
Goto, J ;
Kanazawa, I ;
Davidson, I ;
Tanese, N ;
Takahashi, H ;
Tsuji, S .
NATURE GENETICS, 2000, 26 (01) :29-36